Fibromyalgia Research medicinal marijuana treatments evidence base, Cochrane Reviews, Systematic Reviews

Fibromyalgia Research | Medicinal Cannabis | High THC Formulations

Fibromyalgia Research – does Medicinal Cannabis help?  

Are THC-rich cannabis medications effective for treating symptoms of Fibromyalgia? Find out why a new Dutch study supports further research into treating Fibromyalgia with high THC medical cannabis formulations. Reading time: 2.5 minutes.

Medical Cannabis Research | Fibromyalgia Symptoms

Fibromyalgia is a painful, debilitating condition. Sufferers report chronic physical pain as well as mental ‘cloudiness’ and fatigue that is disruptive to daily functioning, work performance and relationships.

Illness Statistics: Fibromyalgia prevalence

Fibromyalgia is reportedly under-diagnosed.

  • There is no specific test for diagnosing Fibromyalgia.
  • Typically, the condition remains misdiagnosed for many years once symptoms emerge in a patient.

Under-diagnosis or misdiagnosis of Fibromyalgia also stems from the commonality of symptoms with other conditions. Similar symptoms can be found in rheumatoid illnesses such as Lupus, various neurological conditions, mental illnesses and/or sleep disturbances.

Fibromyalgia is estimated to occur somewhat rarely in the population.

Common symptoms of Fibromyalgia

  • Pain, aching and stiffness (worse in the morning)
  • Poor sleep or fatigue
  • Irritable bowel symptoms
  • Concentration and memory difficulties
  • Pain, lasting for at least 3 months
  • Pain is felt on both sides of the body, and above and below the waist

Sources: Mayo Clinic

Fibromyalgia Research | Current evidence-base for Medicinal Cannabis

The question in relation to medical marijuana treatments for Fibromyalgia and/or other intractable health conditions is this:

Can Fibromyalgia symptoms be relieved by prescribing cannabis-based pharmaceuticals containing high levels of THC (e.g., high-THC medical cannabis products)? Does cannabis medication significantly reduce the levels of pain or pain-related dysfunction? If yes, then what is the best dosing strategy and delivery method for the drug(s)?

What potential side effects could lead to discontinuation of the treatment?  And are there any concerns about the potentially addictive qualities of THC-based medicines?

These questions have yet to be answered definitively in the medicinal cannabis research literature 

  • Earlier trials explored synthetic cannabinoid treatments for treating symptoms of pain, sleep disturbances and fatigue.
  • Preliminary studies suggest cannabis and THC-rich medicines might be of help in pain reduction.
  • Study data was impeded by relatively small sample sizes and inconsistent study populations.

The current evidence base remains inconclusive.

Yet a new, albeit small, Dutch study suggested positive indications for treating Fibromyalgia symptoms with high-THC content medications.

Further research trials using THC-cannabis medications for Fibromyalgia patients appears warranted due to:

  • very small study sizes
  • inconclusive or inconsistent research findings in prior medicinal cannabis research and systematic reviews
  • newly formulated marijuana-based medications using varying THC percentages
  • pharmaceutical cannabis formulations currently in early stages of testing and development
  • legalisation issues surrounding cannabinoid medicines
  • product legality differences (worldwide) having prohibited past studies

Cochrane Systematic Reviews | Fibromyalgia Treatments 

Medical Cannabis Research into Fibromyalgia Symptom Relief | Clinical Studies

Cochrane Systematic Reviews essentially combine and analyse data from all relevant studies to assess the significance of findings from clinical trials.  These reviews are rigorously conducted. They explore all existing relevant study data at the time of publication and are required to be updated as new studies emerge. Cochrane Reviews are considered the golden standard evidence-base for illness interventions.

  • Previously-published cannabis medications research studies have indicated some positive, albeit inconsistent, results for conditions such as Fibromyalgia.
  • Systematic Reviews of existing studies, however, provided little support for prescribing cannabinoid medications as a first-line treatment.

But traditional treatments for Fibromyalgia symptoms have equally failed to deliver consistent treatment outcomes and neuropathic pain reductions.  

  • Types of treatments investigated: pharmacological, acupuncture, lifestyle and exercise changes, cannabinoid medications and most recently, high-THC content cannabis formulations
  • The only current medication with strong evidence for reducing neuropathic pain (and Fibromyalgia), according to published Cochrane Reviews, is pregabalin (300 to 600 mg daily).

Cochrane Reviews of Fibromyalgia treatment research

  • Synthetic cannabinoid medications (Cochrane Systematic Review)
  • Seratonin and noradrenaline reuptake inhibitors (e.g., anti-depressant medications)
  • Antipsychotics and various combinations of drugs
  • Physical activity and exercising
  • Acupuncture (Cochrane Systematic Review)

Overall, the literature affirming the efficacy of medical cannabis for conditions such as Arthritis and Fibromyalgia remains sparse and/or inconclusive. 

But with new formulations of cannabis medications containing high THC levels…new questions are emerging in medicine.

Can high THC content medical marijuana formulations relieve common symptoms in Fibromyalgia patients? Possibly yes.

There isn’t enough data to validate the efficacy and safety of these medications at the current time.  Yet where existing treatments have failed patients, some cannabis clinical trials showed promise, with THC formulation variances prime for future research studies.

  • Robust data is not available at the current time yet some studies suggest medicinal cannabis (medical marijuana) and THC-formulations may help relieve chronic pain by 30% to 50%.
  • These are significant pain reductions that could change lives; but commonly reported side effects may limit drug tolerance or temporarily impede daily functioning
  • Common side effects reported by trial patients included dizziness, nausea, dry mouth and drowsiness

Fibromyalgia - medical-cannabis-research-fibromyalgia-treatments-news1

FUTURE Fibromyalgia Treatment considerations

Systematic reviews indicate research results are either inconclusive or of limited due to very small sample sizes.

That noted, as cannabis becomes legalised in more countries, more Universities and Hospitals can lead, or participate in, multi-site clinical research studies.

  • High-THC formulations appear worthy of further clinical research trials involving larger populations
  • Commonly reported side effects that may limit drug tolerance should be explored
  • It is feasible that adjusting THC formulations will alter side effect complaints

A new Dutch study explored high THC content medications in 20 study participants. Findings indicated significant reductions in self-reported pain and an improvement in pain-associated symptoms.

Expect more robust efficacy and safety data to emerge in the next few years.

Future Fibromyalgia treatment research is necessary to explore the effectiveness of high-THC-cannabis medications, as reported by Cannabis Health News (UK).

Review the Cannabis Health New’s articles into cannabis research; including the Dutch study into Fibromyalgia treatments using high-THC content cannabis medications.

Due to drug-legality issues, however, studies into medicinal marijuana treatments for specific illnesses, such as Fibromyalgia, are predomantly lacking in size and scope.  Researchers have only recently begun studies with adequate participant sizes and sufficiently long follow-up periods. These upcoming cannabis studies will create a more robust evidence base for cannabis-related medical decision-making, including dosing requirements and potential side effects.

Golden Standard Clinical Research designs for medicinal cannabis 

Good study designs will feature:

  • larger study populations (higher participant numbers, over 2,000 per study versus a few hundred)
  • double-blind, randomised control trials (RCTs)
  • standardised formulas, medication delivery methods and medication sources
  • consistency of baseline dosing

Future medical cannabis research will also benefit from:

  • higher participation rates and multi-site, cross-country designs
  • longer follow-up periods and 5-year data-analyses
  • varying formulations with evidence-based dosing standards, followed by larger studies
  • consistent data collection protocols and time frames across participating study sites
  • more detailed reporting of symptoms, medication tolerance, pharmaceutical prescription compliance and side effects
  • compatible study designs including data analyses and reporting methodologies
  • Read more at Designing a Medicinal Cannabis Clinical Trial

Medicinal Cannabis trials should be designed as double-blind, randomised control trials (RCTs), with larger study sizes and consistent data point collection time points,  measurement tools and time frames. Longer-term follow-up assessments should also be included in the study designs.

Here’s what to look for in future clinical trials into medicinal cannabis efficacy, side effects and safety

  • Look for double-blind clinical studies comparing cannabis-derived medications and CBD to traditional medications, exploring efficacy, dosing levels, patient safety and adverse effects (SAEs).
  • Large study sizes and multi-site studies will be of benefit.
  • Open disclosure of the pharmaceutical formulations could assist with study design consistencies.
  • However, most pharmaceutical manufacturing companies are rushing to secure drug patents as research continues, which means studies involving the same formulations will be limited in certain cases.

Article Summary: Existing medicinal cannabis research reporting is largely based on case studiesanecdotal reports or smaller-sized studies.  Multi-site studies are less common due to former legality constraints.

Symptom relief from using medicinal cannabis or THC-rich products are often reported. But studies show inconsistency and drug tolerance differences. The result is that robust data is yet to be found.

new Dutch study, however, supports further investigations into high-TCH medicinal cannabis medications for people with chronic pain from Fibromyalgia.  The trial was small, but promising for patients where current treatment approaches have had limited effects.  Read more at Cannabis Health (UK).